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Abstract An optimal dosage regimen of sitaﬂoxacin was
considered based on a pharmacokinetics and pharmaco-
dynamics (PK–PD) analysis in patients with community-
acquired respiratory tract infections (RTI). A population
pharmacokinetic analysis of sitaﬂoxacin was conducted
using clinical data of ﬁve clinical pharmacology studies
and one clinical PK–PD study in patients with RTIs. The
pharmacokinetic parameters in individual patients were
estimated by the Bayesian method to examine any corre-
lation between pharmacokinetics and bacteriological efﬁ-
cacy. Efﬁcacy data were obtained from the clinical PK–PD
study, in which 50 or 100 mg sitaﬂoxacin was administered
twice daily for 7 days. In addition, an efﬁcacy was simu-
lated for a hypothetical dose regimen of 100 mg once
daily. The fAUC0–24h/MIC and the fCmax/MIC of sitaﬂox-
acin at a dose of 50 mg twice daily were 117.5 ± 78.0 and
7.3 ± 4.7 (mean ± SD), respectively. As a result of the
univariate logistic regression analysis, the larger the value
of fAUC0–24h/MIC or fCmax/MIC becomes, the higher the
bacteriological efﬁcacies. The eradication rates for
fAUC0–24h/MIC C 30 and for fCmax/MIC C 2 were 96.4 %
and 96.3 %, respectively. The PK–PD target values of
sitaﬂoxacin for the treatment of mild to moderate RTIs
were considered to be fAUC0–24h/MIC C 30 and fCmax/
MIC C 2. The PK–PD parameters at the regimen of 50 or
100 mg twice daily in patients with RTIs reached the target
values. Furthermore, a 100 mg once-daily regimen was
expected to show similar efﬁcacy based on the PK–PD
simulations.
Keywords Population PK–PD  Sitaﬂoxacin  Optimal
dosage regimen
Introduction
Sitaﬂoxacin, ((-)-7-[(7S)-7-amino-5-azaspiro[2.4]hept-
5-yl]-8-chloro-6-ﬂuoro-1-[(1R,2S)-2-ﬂuorocyclopropyl]-
1,4-dihydro-4-oxo-3-quinolinecarboxylic acid), is a
ﬂuoroquinolone antimicrobial agent developed by
Daiichi Sankyo Co., Ltd. in Japan. Sitaﬂoxacin has a
broad-spectrum antimicrobial activity against aerobic,
anaerobic, gram-positive, and gram-negative bacteria, as
well as Mycoplasma spp. and Chlamydia spp. It also has
a higher antimicrobial activity than other quinolones
against many pathogenic organisms [1, 2].
According to several clinical pharmacology studies that
have been already reported [3–6], sitaﬂoxacin was rapidly
absorbed after oral administration and has a high bio-
availability (89 %). The serum concentration of sitaﬂoxa-
cin increased in a dose-proportional manner between 25
and 200 mg in Japanese healthy male subjects. The
cumulative urinary excretion of unchanged sitaﬂoxacin
within 48 h after administration is approximately 70 % of
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the dose in Japanese subjects. The renal clearance of sita-
ﬂoxacin was approximately 200 ml/min, which indicates
both glomerular ﬁltration and tubular secretion are
involved in the urinary elimination of sitaﬂoxacin [7].
Recently, evidence of a correlation between the phar-
macokinetics (PK) and the pharmacodynamics (PD) of
antimicrobial agents has been accumulating [8–10]. These
studies have reported that a clinical outcome might be
predicted by the parameter indicated by the correlation
between a drug concentration in the plasma/serum and the
minimum inhibitory concentration (MIC) of the drug
against a pathogen. Indices based on PK and PD charac-
teristics often differ according to antimicrobial class. For
example, ﬂuoroquinolones are known as concentration-
dependent agents, and bacterial eradication can be obtained
by ﬂuoroquinolones when the ratio of the area under the
plasma/serum concentration–time curve (AUC) to the MIC
is around 25–30 for gram-positive bacteria and around
100–125 for gram-negative bacteria [8, 11–14].
We conducted the clinical PK–PD study as phase III,
and the clinical efﬁcacy and safety of sitaﬂoxacin have
been previously reported [15]. As a result of a rough
PK–PD analysis in the report, both the clinical and bacte-
riological efﬁcacy of sitaﬂoxacin for the treatment of
respiratory tract infections (RTIs) were shown to be more
than 90 % when either of the following target values was
achieved, AUC0–24h/MIC C 100 or Cmax/MIC C 5. In the
present report, we constructed a population PK (PPK)
model of sitaﬂoxacin using the data of RTI patients in the
clinical PK–PD study and of non-patients in ﬁve clinical
pharmacology studies. The PK parameters in individual
patients were determined using the Bayesian method. In
addition, the correlation between clinical dose regimens
and the bacteriological efﬁcacy of sitaﬂoxacin was exam-
ined using a PK–PD analysis.
All the clinical studies described in this report were
conducted in compliance with the ethical principles origi-
nating in the Declaration of Helsinki, and in compliance
with the Ethics Committees of each participating hospital
or institute, informed consent regulations, and the ICH
Good Clinical Practices Guideline. In addition, these pro-
tocols were approved by the health authority and the
institutional review board or ethics committee.
Subjects and methods
Subjects/patients for PPK and PK–PD analysis
A summary of the clinical trials used for the PPK analysis
of sitaﬂoxacin is shown in Table 1. Serum samples for the
PK evaluation were obtained from the patients with
respiratory tract infections (RTIs), mild to moderate
community-acquired pneumonia, acute exacerbation of
chronic bronchitis, or acute bronchitis, who were enrolled
in a phase III, multi-center, open-label trial [15]. These
patients received 50 or 100 mg of sitaﬂoxacin twice daily
for 7 days. The PPK model was investigated in 137
patients with RTIs as well as 75 non-patients including
healthy subjects, renal-impaired subjects, and elderly sub-
jects enrolled in either of the clinical pharmacology studies
[3–6]. In these clinical pharmacology studies, subjects
received a single dose (25–200 mg) or multiple doses (50
or 100 mg, twice daily, or 100 mg three times daily for
7 days) of sitaﬂoxacin. The creatinine clearance (CLcr) was
calculated using the Cockcroft–Gault equation [17]. The
age of the subjects in the analysis ranged from 20 to
91 years; their weight ranged from 33.5 to 95.0 kg; and
their creatinine clearance ranged from 16 to 178 ml/min.
PK sampling
To estimate the PK parameters, 2 to 5 blood samples (5 ml
each) were obtained from each patient at the point in the
speciﬁed time windows (trough, 1–3 h after dosing, and
4–8 h after dosing) in the clinical PK–PD study. In the
clinical pharmacology studies, 5 to 31 blood samples were
obtained from each subject.
Bioanalytical method
Serum samples were stored at -20 C until analysis. The
serum concentration of sitaﬂoxacin was measured using
HPLC in the clinical pharmacology studies or LC–MS/MS
in the clinical PK–PD study. The lower limit of quantiﬁ-
cation was 0.010 mg/l in both methods. In the LC–MS/MS
method, 0.1 ml serum sample was diluted with a mixture of
H2O/acetic acid (98/2). The mixture was applied to an
Oasis HLB extraction cartridge (30 mg/1 ml; Waters). The
intraassay accuracy and precision of the HPLC method
ranged between -2.7 % and 6.2 %, and below 6.4 %,
respectively, and the interassay accuracy and precision
ranged between -3.0 % and 7.0 %, and below 5.0 %,
respectively. The intraassay accuracy and precision for the
LC–MS/MS method ranged between -1.6 % and 10.4 %,
and below 6.7 %, respectively, and the interassay accuracy
and precision ranged between 0.8 % and 7.8 %, and below
7.7 %, respectively.
Bacteriological examination
The pathogenic organisms were isolated from appropriate
specimens in each patient. Ninety-one strains were isolated
from the patients in the clinical PK–PD study. The MICs of
sitaﬂoxacin were measured using the broth microdilution
method.
J Infect Chemother (2013) 19:858–866 859
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PPK model
The PPK analysis was performed using the nonlinear
mixed-effect model (NONMEM) program (version V) with
a PREDPP library and NM-TRAN preprocessor. The ﬁrst-
order method was used for the estimation. The PK of
sitaﬂoxacin was assumed to follow the one-compartment
model with ﬁrst-order absorption. The basic parameters
were oral clearance (CLt/F), apparent volume of distribu-
tion (Vd/F), and absorption constant (ka), and these
parameters were estimated using a model from the
PREDPP library (ADVAN2 and TRANS2).
The interindividual variability in CLt/F, Vd/F, and ka
was modeled as follows:
Pi ¼ h 1þ gið Þ
where Pi is the parameter for the i-th subject, h is the
typical value of the parameter in the population, and g is a
random interindividual effect of a mean of 0 and a variance
of x2. A covariance matrix between CLt/F and Vd/F was
presumed. The residual variability was modeled as follows:
Cij ¼ Cij þ eij
where Cij and Cij
* represent the j-th observed and predicted
concentration for the i-th subject, respectively, and e is the
random intraindividual effect, which is normally distrib-
uted with a mean of 0 and a variance of r2.
The effect of the covariate was evaluated using a step-
wise forward addition and backward elimination process.
Tested covariates were as follows: CLcr and disease status
on CLt/F; body weight, age, gender, and disease status on
Vd/F; fasting status and age on ka; and fasting status on
F. A change in the objective function value of 6.64 with
freedom unity represented a statistically signiﬁcant
(P\ 0.01) model improvement. A new model was gener-
ated from the basic model by including covariates that were
signiﬁcant and which had the lowest objective function
values (OFV). Based on this new model, the same proce-
dure was repeated on the rest of the covariates. When no
further covariates could be included, a backward elimina-
tion was performed at the 1 % signiﬁcance level.
The bootstrap resampling procedure was repeated 1,000
times and the mean values of each parameter and the 95 %
conﬁdence intervals (2.5–97.5 %) of the ﬁnal model were
determined.
According to the parameters of the PPK analysis
determined above, the effects of changes in the covariates
on the serum concentration proﬁle of sitaﬂoxacin were
analyzed. The steady-state serum concentration–time pro-
ﬁles after the repeated oral administration of 50 mg sita-
ﬂoxacin twice daily were plotted for individuals who were
representative of speciﬁc demographics.
PK exposure values of sitaﬂoxacin in patients
with respiratory tract infection
The individual PK parameters, AUC0–24h, Cmax, and trough
value (12 h after administration), in the steady state after
repeated oral administration twice daily were estimated
using the Bayesian method. The free AUC0–24h
(fAUC0–24h) and free Cmax (fCmax) of sitaﬂoxacin were
calculated by correcting AUC0–24h or Cmax with unbound
fraction of serum protein binding (0.388).
PK–PD indices for efﬁcacy of sitaﬂoxacin in patients
with respiratory tract infection
The PK–PD analysis was performed in 74 patients whose
bacteriological efﬁcacy and MIC data for sitaﬂoxacin
against the pathogen(s) were available (91 strains). Indi-
vidual fAUC0–24h/MIC and fCmax/MIC values were calcu-
lated using the individual PK parameters and MIC values
Table 1 Summary of clinical trials of sitaﬂoxacin used in the present analysis
Study no. Subject description Dosage Number of
subjects/
patients
Number of
serum
samples
Reference
DU6859-01 Healthy male subjects (phase I) 25, 50, 100, or 200 mg, single dose 24 310 [3, 4]
DU6859-01, 02
DU6859a-03
Healthy male subjects (phase I) 50 or 100 mg, twice daily, and
100 mg, three times daily, 7 days
18 535 [4, 16]
DU6859a-19 Elderly patients with chronic respiratory
tract disease (clinical pharmacology)
50 or 100 mg, single dose 10 50 [16]
DU6859a-28 Healthy male elderly or nonelderly
subjects (clinical pharmacology)
100 mg, single dose 11 101 [6]
DU6859a-37 Renal-impaired subjects (clinical
pharmacology)
50 mg, single dose 12 148 [5]
DU6859a-44 Patients with respiratory tract infection
(phase III, PK–PD study)
50 or 100 mg, twice daily, 7 days 137 354 [15]
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against the pathogens. The correlations between bacterio-
logical efﬁcacy and the PK–PD parameters, fAUC0–24h/
MIC or fCmax/MIC, were examined using univariate
logistic regression analysis. In this analysis, the PK–PD
parameters were treated as continuous variables. Patients
were grouped according to their fAUC0–24h/MIC or fCmax/
MIC values, and the bacterial eradication rate was calcu-
lated for each group. The achievement rates of the
fAUC0–24h/MIC and fCmax/MIC target values were also
calculated when sitaﬂoxacin was administered at a dose of
50 or 100 mg twice daily. Furthermore, these PK–PD
parameters at a dose of 100 mg once daily were simulated
using the data of the clinical PK–PD study. The MIC
values of the 91 strains in this study were combined with
the PK parameters in 74 patients, and the PK–PD param-
eters in 6,734 patients (PK in 74 patients 9 MIC in 91
strains), and the attainment rates of the fAUC0–24h/MIC and
fCmax/MIC target values were also calculated.
Results
PPK parameters of sitaﬂoxacin
A total of 1,497 serum concentration data points from 212
subjects/patients were used for the PPK analysis. The
serum concentration–time proﬁles after the last dose are
shown in Fig. 1. In the forward selection step, the CLcr and
disease status had a statistically signiﬁcant effect on CLt/F,
body weight and age on Vd/F, and age and fasting status on
ka. All the selected covariates were conﬁrmed to be sta-
tistically signiﬁcant in the backward elimination step.
However, the results of a bootstrap calculation showed that
the effect of age on ka was not statistically signiﬁcant, and
the effect was removed from the ﬁnal model. The PPK
parameters for the ﬁnal model, and the mean and 95 % CI
of the parameters estimated using the bootstrap calculation,
are shown in Table 2. The correlations between individual
PK parameters estimated using the Bayesian method and
covariates were examined. CLt/F appeared to be propor-
tional to CLcr with the population mean ratio of 2.58 and
was 1.27 times higher in healthy volunteers than patients
with RTIs. Vd/F was correlated with body weight in a
proportional manner, and the slope for the elderly patients
differed from that for nonelderly patients. The ka values
after fasting were higher than those after feeding.
The serum concentration of sitaﬂoxacin after the repe-
ated oral administration of 50 mg twice daily in typical
patients was estimated using the ﬁnal PPK parameters. The
serum concentration in patients whose CLcr value was 20
or 40 ml/min was much higher than that in patients with a
CLcr value of 75 ml/min (Fig. 2). In contrast, a change in
body weight, age, and fasting status slightly affected the
serum concentration of sitaﬂoxacin (Fig. 2). These results
show that CLcr is the most important factor for predicting a
change in the serum concentration of sitaﬂoxacin.
PK exposure values of sitaﬂoxacin in patients
with respiratory tract infection
The individual PK parameters, Cmax, AUC0–24h, and trough
concentration, at steady state after the repeated oral
administration of sitaﬂoxacin at a dose of 50 or 100 mg
twice daily were calculated using the Bayesian method.
The mean ± SD of the Cmax in the 50 and 100 mg groups
were 0.57 ± 0.21 and 1.17 ± 0.45 mg/l, respectively. The
mean ± SD of the AUC0–24h in the 50 and 100 mg groups
were 9.38 ± 4.24 and 17.16 ± 6.52 mgh/l, respectively.
PK–PD indices for sitaﬂoxacin in patients
with respiratory tract infection
The MICs of sitaﬂoxacin against pathogens used for the
PK–PD analysis are shown in Table 3. The major isolates
were Streptococcus pneumoniae and Haemophilus inﬂu-
enzae. The MICs of sitaﬂoxacin against these pathogens
were distributed at B 0.025 mg/l and from B 0.025 to
0.39 mg/l, respectively. The mean ± SD of the fCmax/MIC
in the 50 and 100 mg twice-daily groups were 7.3 ± 4.7
and 12.6 ± 6.4, respectively, and fAUC0–24h/MIC in the 50
and 100 mg twice-daily groups were 117.5 ± 78.0 and
198.6 ± 101.6, respectively.
As a result of an univariate logistic regression analysis,
larger values of fAUC0–24h/MIC or fCmax/MIC were shown
to be correlated with a higher bacteriological efﬁcacy of
sitaﬂoxacin. The effects of the PK–PD parameters were
statistically signiﬁcant (Fig. 3).
The correlation between the bacteriological efﬁcacy of
sitaﬂoxacin and PK–PD variables in RTI patients is shown
in Table 4. The eradication rate was 96.4 % when the
fAUC0–24h/MIC was C 30. In addition, the eradication rate
was 96.3 % when the fCmax/MIC was C 2. In contrast, the
eradication rates in the fAUC0–24h/MIC\ 30 and in fCmax/
MIC\ 2 decreased to 25.0 % and 33.3 %, respectively.
The attainment of these PK–PD target values is shown
in Table 5. The attainment rates of fAUC0–24h/MIC C 30
and fCmax/MIC C 2 for the 50 mg twice-daily regimen of
sitaﬂoxacin were 90.8 % and 89.5 %, respectively. The
attainment rates of fAUC0–24h/MIC C 30 and fCmax/
MIC C 2 for the 100 mg twice-daily regimen were both
93.3 %. The results of the simulation showed that the
attainment rate of fAUC0–24h/MIC C 30 and fCmax/
MIC C 2 for a 100 mg once-daily regimen were also more
than 90 %. Furthermore, these results were almost the
same as those that compared each clinical efﬁcacy rate
(92.3 % at a dose of 50 mg; 93.1 % at a dose of 100 mg),
J Infect Chemother (2013) 19:858–866 861
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including patients in whom the causative pathogen could
not be clariﬁed.
Discussion
In the present study, we conducted a PPK analysis
of sitaﬂoxacin in patients with RTIs before an
exposure–response analysis. We determined the serum
concentrations of sitaﬂoxacin in patients with RTIs
enrolled in a clinical PK–PD study and analyzed these
data together with data from non-patients including
healthy subjects, renal-impaired subjects, and elderly
subjects. The results suggested that CLcr, body weight,
age, disease status, and fasting status inﬂuenced the PK of
sitaﬂoxacin. The CLcr considerably affected the serum
concentration of sitaﬂoxacin, whereas other factors, such
as body weight, age, and fasting status, had only slight
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time proﬁles of sitaﬂoxacin in
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circles 50 mg, n = 109; total
137 patients) and in subjects
participating in clinical
pharmacology studies (right:
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Table 2 Population pharmacokinetic parameters estimates for the ﬁnal model
Parameter Estimate (SE) Bootstrap result
Mean (95 % CI)
(CLt/F)/CLcr 2.58 (0.0810) 2.58 (2.42, 2.75)
Vd/F (l/kg) 1.72 (0.0513) 1.73 (1.63, 1.85)
ka (h
-1) 1.67 (0.470) 1.86 (1.02, 3.71)
hstatus onCLt=F 1.27 (0.0881) 1.28 (1.12, 1.46)
hAge onVd=F 1.28 (0.103) 1.27 (1.09, 1.52)
hFOODon ka 2.31 (0.410) 2.29 (1.29, 3.55)
xCLt=F
2 0.0757 (0.0108) 0.0740 (0.0511, 0.0959)
xVd=F
2 0.087 (0.0236) 0.091 (0.045, 0.150)
xCLt=F;Vd=F 0.0522 (0.0122) 0.0518 (0.0278, 0.0819)
xka
2 4.57 (3.18) 6.71 (1.60, 22.65)
r2 0.00923 (0.00125) 0.00901 (0.00668, 0.01150)
CLt=Fðl/hÞ ¼ 2:58 CLCR  60=1; 000 ðpatientÞ2:58 CLCR  60=1; 000 1:27 ðhealthy volunteerÞ

Vd=Fðl/kgÞ ¼ 1:72 BW ðage\65Þ1:72 BW 1:28 ðage 65Þ

kaðh1Þ ¼ 1:67 ðfedÞ1:67 2:31 ðfastedÞ

BW body weight (kg), CLcr creatinine clearance (Cockcroft–Gault; ml/min)
862 J Infect Chemother (2013) 19:858–866
123
effects on Cmax and Tmax. This ﬁnding is consistent with
the fact that the cumulative urinary excretion of unchan-
ged drug after oral administration amounts to approxi-
mately 70 % in Japanese subjects [4]. Levoﬂoxacin is
primarily eliminated through the kidneys, similar to sita-
ﬂoxacin, and patients with renal impairment are known to
have increased serum concentration levels of these drugs
[18, 19]. Therefore, a reduction in the dose or frequency
of administration is recommended in renal-impaired
patients.
After the repeated oral administration of sitaﬂoxacin at a
dose of 50 or 100 mg twice daily in patients with RTIs,
the Cmax was 0.57 and 1.17 mg/l, respectively, and the
AUC0–24h was 9.38 and 17.16 mgh/l, respectively. The
Cmax and AUC0–inf in healthy Japanese individuals treated
with a 50 mg single dose of sitaﬂoxacin were
0.51 ± 0.14 mg/l and 2.62 ± 0.53 mgh/l, respectively
[4]. The AUC0–24h value that was calculated in this study
was two times higher than the AUC value per dosing
interval (AUC0–tau). However, taking this into consider-
ation, the AUC of patients with RTIs was higher than that
of healthy individuals. Renal function and creatinine
clearance are known to decline with age [20]. Therefore,
the elimination of drugs by renal excretion is often
delayed and, consequently, an increase in the serum level
is observed in elderly patients. Many elderly patients
with declined renal function were enrolled in the clini-
cal PK–PD study. Thus, the results for these subjects
might have led to the higher serum concentrations
of sitaﬂoxacin compared with the results in healthy
individuals.
For ﬂuoroquinolones, fCmax/MIC and fAUC/MIC are
used to predict an antibacterial effect and the emergence of
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Fig. 2 Effects of various covariates on serum concentration–time
proﬁles of sitaﬂoxacin. CLcr creatinine clearance (Cockcroft–Gault;
ml/min)
Table 3 Pathogens isolated
from patients with respiratory
tract infections (91 strains)
Pathogens Number of strains Minimum inhibitory concentration (MIC)
range of sitaﬂoxacin (mg/l)
Gram-positive cocci
Staphylococcus aureus 11 B0.025
Streptococcus pneumoniae 22 B0.025–0.39
Gram-negative bacilli
Moraxella catarrhalis 12 B0.025
Citrobacter koseri 1 B0.025
Klebsiella pneumoniae 4 B0.025–0.78
Enterobacter aerogenes 1 B0.025
Haemophilus inﬂuenzae 23 B0.025
Haemophilus parainﬂuenzae 5 B0.025–0.39
Pseudomonas aeruginosa 4 0.1–0.78
Acinetobacter calcoaceticus 1 B0.025
Other
Mycoplasma pneumoniae 7 0.015–0.03
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123
antibacterial resistance [21, 22]. We previously reported
the PK–PD parameters in patients with RTIs receiving 50
or 100 mg of sitaﬂoxacin twice daily [15]. In this previous
study, the eradication rate of causative organisms increased
when the Cmax/MIC was more than 5 and/or the AUC0–24h/
MIC was more than 100. In the present study, we evaluated
the PK–PD target value and the attainment rate of this
target when 50 or 100 mg of sitaﬂoxacin was simulated
twice daily based on the results of the clinical PK–PD
study. A fCmax/MIC value C 2 and/or a fAUC0–24h/MIC
value C 30 were suggested to be necessary to eradicate
causative organisms in patients with RTIs. When threshold
values of Cmax/MIC (5) and AUC0–24h/MIC (100) are
converted to fCmax/MIC and fAUC0–24h/MIC using
unbound fraction of serum protein binding (0.388) of
sitaﬂoxacin, the threshold fCmax/MIC and fAUC0–24h/MIC
values are calculated as 2 and 39, respectively. These
values are consistent with the present results for the target
values of fCmax/MIC (2) and fAUC0–24h/MIC (30). Actu-
ally, the 50 mg twice-daily regimen was effective for the
treatment of mild to moderate community-acquired RTIs,
in addition to the 100 mg twice-daily regimen. Further-
more, a 100 mg once-daily regimen of sitaﬂoxacin was
also suggested to have an efﬁcacy similar to that of the
50 mg twice-daily regimen, based on the PK–PD simula-
tion results.
Sitaﬂoxacin has strong antimicrobial activity against a
broad range of gram-positive and gram-negative bacteria
including anaerobic bacteria, as well as against atypical
pathogens. The MIC90 of sitaﬂoxacin against S. pneumo-
niae, H. inﬂuenzae, and Moraxella catarrhalis, which
are major pathogens in respiratory tract infections,
are\ 0.06,\ 0.01, and\ 0.01 mg/l, respectively [2].
Furthermore, sitaﬂoxacin inhibits the activity of both the
DNA gyrase and the topoisomerase IV enzymes. The
inhibitory activity against these enzymes was greater than
that of comparative ﬂuoroquinolones [23]. Therefore, we
consider that sitaﬂoxacin administered orally at a dose of
even 50 mg twice daily is likely to be adequately effective
against major pathogens causing RTIs.
In conclusion, we conducted PPK and PK–PD analyses
to estimate PK–PD parameters of sitaﬂoxacin in patients
with RTIs. The required PK–PD target values of sitaﬂox-
acin for the treatment of mild to moderate RTIs were
considered to be fAUC0–24h/MIC C 30 and fCmax/
MIC C 2. The PK–PD parameters with 50 or 100 mg twice
daily in major pathogens of RTIs reached these PK–PD
target values for Staphylococcus aureus, Streptococcus
pneumoniae,M. catarrhalis, H. inﬂuenzae, and partially for
Klebsiella pneumoniae and Pseudomonas aeruginosa.
PK-PD variables Wald χ2 P value Odds ratio (95 % CI)
f AUC0-24h/MIC 12.9 0.0003 1.48 (1.19, 1.83)
f Cmax /MIC 11.9 0.0006 1.77 (1.28, 2.45)
f Cmax/MICf AUC0-24h/MIC
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Fig. 3 Associations between
bacteriological efﬁcacy and
pharmacokinetics and
pharmacodynamics (PK–PD)
variables (univariate logistic
regression; number of strains
used for evaluation = 91)
Table 4 Bacteriological effect of sitaﬂoxacin and pharmacokinetics
and pharmacodynamics (PK–PD) variables in respiratory tract infec-
tions (RTIs)
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Furthermore, a 100 mg once-daily regimen was expected
to show similar efﬁcacy because this regimen also reached
the target values based upon the PK–PD simulations.
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